Mafalda Cacciottolo

Mafalda Cacciottolo

Auto-generated profile, based on publicly available information

Mafalda Cacciottolo

Affiliation Capricor Therapeutics, Inc., San Diego, California, United States of America

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
MCMafalda Cacciottolo
Mafalda Cacciottolo
JNJustin B Nice
Justin B Nice
YLYujia Li
Yujia Li
MLMichael J. LeClaire
Michael J. LeClaire
RTRyan Twaddle
Ryan Twaddle
MSMinghao Sun
Minghao Sun
The pandemic emergency has brought to light the need for a new generation of rapidly developed vaccines that induce longer-lasting, potent, and broader immune responses. While the mRNA vaccines played a critical role during the emergency in reducing SARS-CoV-2 hospitalization rates and deaths, more efficient approaches are needed.

1 July 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
MCMafalda Cacciottolo
Mafalda Cacciottolo
TMTodd E. Morgan
Todd E. Morgan
CFCaleb E. Finch
Caleb E. Finch

22 August 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMafalda Cacciottolo
Mafalda Cacciottolo
YLYujia Li
Yujia Li
JNJustin B. Nice
Justin B. Nice
MLMichael J. LeClaire
Michael J. LeClaire
RTRyan Twaddle
Ryan Twaddle
MSMinghao Sun
Minghao Sun
Exosomes are emerging as potent and safe delivery carriers for use in vaccinology and therapeutics. A better vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to provide improved, broader, longer lasting neutralization of SARS-CoV-2, a more robust T cell response, enable widespread global usage, and further enhance the safety profile of vaccines given the likelihood of repeated booster vaccinations. Here, we use Capricor’s StealthXTM platform to engineer exosomes to express native SARS-CoV-2 spike Delta variant (STX-S) protein on the surface for the delivery of a protein-based vaccine for immunization against SARS-CoV-2 infection. The STX-S vaccine induced a strong immunization with the production of a potent humoral immune response as demonstrated by high levels of neutralizing antibody not only against the delta SARS-CoV-2 virus but also two Omicron variants (BA.1 and BA.5), providing broader protection than current mRNA vaccines. Additionally, both CD4+ and CD8+ T cell responses were increased significantly after treatment. Quantification of spike protein by ELISA showed that only nanograms of protein were needed to induce a potent immune response. This is a significantly lower dose than traditional recombinant protein vaccines with no adjuvant required, which makes the StealthXTM exosome platform ideal for the development of multivalent vaccines with a better safety profile. Importantly, our exosome platform allows novel proteins, or variants in the case of SARS-CoV-2, to be engineered onto the surface of exosomes in a matter of weeks, comparable with mRNA vaccine technology, but without the cold storage requirements necessary for mRNA vaccines. The ability to utilize exosomes for cellular delivery of proteins, as demonstrated by STX-S, has enormous potential to revolutionize vaccinology by rapidly facilitating antigen presentation at an extremely low dose resulting in a potent, broad antibody response.

11 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMafalda Cacciottolo
Mafalda Cacciottolo
JNJustin B Nice
Justin B Nice
YLYujia Li
Yujia Li
MLMichael J. LeClaire
Michael J. LeClaire
RTRyan Twaddle
Ryan Twaddle
MSMinghao Sun
Minghao Sun
Current approved vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused solely on the spike protein to provide immunity. The first vaccines were developed rapidly using spike mRNA delivered by lipid nanoparticles but required ultra-low storage and have had limited immunity against variations in spike. Subsequently, protein-based vaccines were developed which offer broader immunity but require significant time for development and use of an adjuvant to boost immune response. Here, exosomes were used to deliver a bi-valent protein-based vaccine, in which two independent viral proteins were used. Exosomes were engineered to express either SARS-CoV-2 Delta spike (Stealth X-Spike, STX-S) or the more conserved nucleocapsid (Stealth X-Nucleocapsid, STX-N) protein on the surface. When administered as single product (STX-S or STX-N) or in combination (STX-S+N), both STX-S and STX-N induced a strong immunization with the production of a potent humoral and cellular immune response. Interestingly, these results were obtained with administration of only nanograms of protein and without adjuvant. In two independent animal models (mouse and rabbit), administration of nanograms of the STX-S+N vaccine resulted in increased antibody production, potent neutralizing antibodies with cross-reactivity to other variants of spike and strong T-cell responses. Importantly, no competition in immune response was observed, allowing for delivery of nucleocapsid with spike to offer improved SARS-CoV-2 immunity. These data show that the StealthX TM exosome platform has an enormous potential to revolutionize vaccinology by combining the advantages of mRNA and recombinant protein vaccines into a superior, rapidly generated, low dose vaccine resulting in potent, broader immunity.